Financial Performance Forecast - The company expects a net profit attributable to shareholders of the parent company for the first half of 2024 to be between 291.38 million and 311.38 million CNY, representing a year-on-year increase of 122%-137%[2]. - The net profit attributable to shareholders of the parent company, after deducting non-recurring gains and losses, is expected to be between 88.16 million and 99.66 million CNY, reflecting a year-on-year increase of 12%-27%[3]. - The previous year's net profit attributable to shareholders of the parent company was 131.38 million CNY, with a net profit of 78.66 million CNY after deducting non-recurring gains and losses[4]. Factors Influencing Profit - The increase in profit is attributed to the continuous improvement in operational performance and product structure optimization, leading to steady revenue growth[5]. - The completion of land transfer procedures for the company's southern plant is expected to have a positive impact on the company's financial results[5]. Forecast Reliability - The performance forecast is based on preliminary calculations and has not been audited by registered accountants[3]. - There are no significant uncertainties affecting the accuracy of this performance forecast[6]. - Investors are advised to pay attention to investment risks as the forecast data is preliminary and subject to change upon the official release of the 2024 semi-annual report[7].
鲁抗医药(600789) - 2024 Q2 - 季度业绩预告